Dipartimento di Epidemiologia, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Eur Urol. 2011 Jul;60(1):1-15. doi: 10.1016/j.eururo.2011.03.047. Epub 2011 Apr 5.
In recent decades, there have been substantial changes in mortality from urologic cancers in Europe.
To provide updated information, we analyzed trends in mortality from cancer of the prostate, testis, bladder, and kidney in Europe from 1970 to 2008.
DESIGN, SETTING, AND PARTICIPANTS: We derived data for 33 European countries from the World Health Organization database.
We computed world-standardized mortality rates and used joinpoint regression to identify significant changes in trends.
Mortality from prostate cancer has leveled off since the 1990s in countries of western and northern Europe, particularly over the last few years while it was still rising in Bulgaria, Romania, and Russia. In the European Union (EU), it reached a peak in 1995 at 15.0 per 100 000 men and declined to 12.5 per 100 000 in 2006. Mortality from testicular cancer has steadily declined in most countries in western and northern Europe since the 1970s. The declines were later and appreciably lower in central/eastern Europe. In EU, rates declined from 0.75 in 1980 to 0.32 per 100 000 men in 2006, with stronger declines up to the late 1990s and an apparent leveling off in rates thereafter. Over the last 15 years, mortality from bladder cancer has declined in most European countries in both sexes. The major exceptions were Bulgaria, Poland, and Romania. In the EU, bladder cancer mortality was stable until 1992 and declined thereafter from 7.3 to 5.5 per 100 000 men and from 1.5 to 1.2 per 100 000 women in 2006. Mortality from kidney cancer increased throughout Europe until the early 1990s and leveled off thereafter in many countries, except in a few central and eastern ones. Between 1994 and 2006, rates declined from 4.9 to 4.3 per 100 000 in EU men and from 2.1 to 1.8 per 100 000 in EU women.
Over the last two decades, trends in urologic cancer mortality were favorable in Europe, with the exception of a few central and eastern countries.
近几十年来，欧洲泌尿生殖系统癌症的死亡率发生了重大变化。
为了提供最新信息，我们分析了 1970 年至 2008 年欧洲前列腺癌、睾丸癌、膀胱癌和肾癌死亡率的趋势。
设计、地点和参与者：我们从世界卫生组织数据库中获取了 33 个欧洲国家的数据。
我们计算了世界标准化死亡率，并使用联合点回归来确定趋势的显著变化。
自 20 世纪 90 年代以来，西欧和北欧国家的前列腺癌死亡率已趋于平稳，尤其是在过去几年中，保加利亚、罗马尼亚和俄罗斯的死亡率仍在上升。在欧盟（EU），其死亡率在 1995 年达到峰值，为每 10 万人 15.0 人，2006 年降至每 10 万人 12.5 人。自 20 世纪 70 年代以来，西欧和北欧大多数国家的睾丸癌死亡率一直在稳步下降。中欧和东欧的下降时间较晚，幅度也较小。在欧盟，死亡率从 1980 年的 0.75 降至 2006 年的每 10 万人 0.32 人，直到 20 世纪 90 年代末下降幅度更大，此后死亡率似乎趋于平稳。在过去的 15 年里，大多数欧洲国家男性和女性的膀胱癌死亡率都有所下降。保加利亚、波兰和罗马尼亚是主要的例外。在欧盟，膀胱癌死亡率在 1992 年前保持稳定，此后从每 10 万人 7.3 人下降到 5.5 人，从每 10 万人 1.5 人下降到 1.2 人。在 2006 年。在整个欧洲，肾癌死亡率一直上升，直到 20 世纪 90 年代初，此后除了少数中欧和东欧国家外，许多国家的死亡率都趋于平稳。在 1994 年至 2006 年期间，欧盟男性的死亡率从每 10 万人 4.9 人下降到 4.3 人，欧盟女性的死亡率从每 10 万人 2.1 人下降到 1.8 人。
在过去的二十年中，除了少数中欧和东欧国家外，欧洲泌尿生殖系统癌症死亡率的趋势较为有利。
